相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extravasation of polymeric nanomedicines across tumor vasculature
Michael K. Danquah et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
Srikala S. Sridhar et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
Ye-Hong Kuang et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery
Feng Li et al.
BIOMACROMOLECULES (2010)
Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas
Angel M. Carcaboso et al.
CANCER RESEARCH (2010)
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines
D. M. Collins et al.
INVESTIGATIONAL NEW DRUGS (2010)
Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100
Feng Li et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP
Xiaowei Dong et al.
CANCER RESEARCH (2009)
Expression of Multidrug Resistance Proteins in Prostate Cancer Is Related With Cell Sensitivity to Chemotherapeutic Drugs
Catherine Sanchez et al.
PROSTATE (2009)
Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling
Greg Shaw et al.
Cancer Cell International (2008)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Chun-ling Dai et al.
CANCER RESEARCH (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
What are determining factors for micelle carriers? Consideration stable drug incorporation into polymeric on physical and chemical characters of the micelle inner core
Tatsuhiro Yamamoto et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: An update of recent developments
Neeltje Steeghs et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents
Helen M. Coley et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Copoly(styrene-maleic acid) - Pirarubicin micelles: High tumor-targeting efficiency with little toxicity
K Greish et al.
BIOCONJUGATE CHEMISTRY (2005)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
